Viropro Inc. Enters Into Contract for the Development of a High Volume Sales Targeted Monoclonal Antibody

MONTREAL, March 19, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Viropro Inc. (OTCBB:VPRO) ("Viropro") is pleased to announce that an important contractual partnership has been signed with the National Research Council- Biotechnology Research Institute (NRC-BRI) for the development of one of the company's main products, a targeted high volume sales Monoclonal Antibody. NRC-BRI has granted Viropro an exclusive worldwide license for cutting edge intellectual property designed to increase the production of specific biopharmaceutical products in manufacturing processes.